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Schizophrenia is a genetically related mental illness, in which the majority of genetic
alterations occur in the non-coding regions of the human genome. In the past
decade, a growing number of regulatory non-coding RNAs (ncRNAs) including
microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have been identified to
be strongly associated with schizophrenia. However, the studies of these ncRNAs in the
pathophysiology of schizophrenia and the reverting of their genetic defects in restoration
of the normal phenotype have been hampered by insufficient technology to manipulate
these ncRNA genes effectively as well as a lack of appropriate animal models.
Most recently, a revolutionary gene editing technology known as Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated nuclease 9
(Cas9; CRISPR/Cas9) has been developed that enable researchers to overcome
these challenges. In this review article, we mainly focus on the schizophrenia-related
ncRNAs and the use of CRISPR/Cas9-mediated editing on the non-coding regions
of the genomic DNA in proving causal relationship between the genetic defects
and the pathophysiology of schizophrenia. We subsequently discuss the potential of
translating this advanced technology into a clinical therapy for schizophrenia, although
the CRISPR/Cas9 technology is currently still in its infancy and immature to put into use
in the treatment of diseases. Furthermore, we suggest strategies to accelerate the pace
from the bench to the bedside. This review describes the application of the powerful
and feasible CRISPR/Cas9 technology to manipulate schizophrenia-associated ncRNA
genes. This technology could help researchers tackle this complex health problem
and perhaps other genetically related mental disorders due to the overlapping genetic
alterations of schizophrenia with other mental illnesses.
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INTRODUCTION
Schizophrenia is a severe mental illness, in which patients exhibit both mental and behavioral
dysfunction mainly associated with neurodevelopmental abnormality. Indeed, schizophrenia
is considered as a neurodevelopmental disorder (Marenco and Weinberger, 2000). To date,
the pathological causes underlying the onset and progression of schizophrenia remain unclear.
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A wealth of science-based evidence has indicated that
schizophrenia is a genetically related mental illness that is
inherited in approximately 80% of cases (Cardno et al., 1999)
and that certain alterations in the genomic DNA inherited
from the parents are likely to contribute to disease onset in
late adolescence or early adulthood (International Schizophrenia
Consortium et al., 2009; Costain et al., 2013; Human Molecular
Genetics). Decades of research have shown that the interplay
between genes and environmental factors largely contribute to
the development of schizophrenia (Owen et al., 2016). It has
been found that the majority of genetic alterations occur in the
non-coding regions of human genome, from which regulatory
non-coding RNAs (ncRNAs), mainly microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs), are transcribed. miRNAs
and lncRNAs are two major regulatory ncRNAs with little
capacity to encode proteins and have differences in size, location
and biological function. miRNAs play a vital role in the
modulation of gene expression, mainly via post-transcriptional
destabilization of target mRNAs that harbor one or more
complementary sites with miRNAs, translational repression, or
a combination of the two molecular mechanisms (Bartel, 2004,
2009). While lncRNAs are defined as regulatory ncRNAs with
a size longer than 200 nt in length. In contrast to miRNAs,
our knowledge with respect to the molecular mechanism
whereby lncRNAs function remains largely unexplored (Ponting
et al., 2009; Wilusz et al., 2009). Recently, a growing number
of lncRNAs have been reported to be associated with a
broad range of diseases, including mental illnesses such as
schizophrenia (Barry et al., 2014; Merelo et al., 2015; Rao
et al., 2015). miRNAs and lncRNAs as two large groups of
regulatory ncRNAs are highly expressed in the brain where
they act as important modulators of genes essential for
maintaining proper brain development and function. This is
of particular importance because it has been well documented
that abnormal brain development, maturation and plasticity
have been strongly linked to schizophrenia. For instance,
manipulation of schizophrenia-associated miRNAs such as miR-
132/miR-121 and miR-219 has been reported to alter an
activity-dependent neuronal maturation and plasticity at synapse
(Nudelman et al., 2010; Tognini et al., 2011; Mellios and
Sur, 2012). Further studies have shown that these miRNAs
function through either directly regulating synthesis of proteins
which are essential for plasticity at the synapse or interacting
with transcription factors which are likely to modulate more
enduring neuroplastic changes (Smalheiser and Lugli, 2009;
Mellios and Sur, 2012). These recent findings of schizophrenia-
associated miRNAs suggest that the biological implication of
dysregulation of the miRNAs and their targeted genes are
profound for schizophrenia. Considering the magnitude of
miRNA alterations and their broad effects on target genes
in schizophrenia, the schizophrenia-associated miRNAs might
be important for the pathogenesis of schizophrenia. Over
past years, an increasing number of schizophrenia-associated
ncRNAs such as miR-137, lncRNA Gomafu, etc., has been
identified, and the correlation of their genetic alterations with
the pathogenesis of schizophrenia has been characterized (Sone
et al., 2007; International Schizophrenia Consortium et al., 2009;
Schizophrenia Psychiatric Genome-Wide Association Study
(GWAS) Consortium, 2011; Barry et al., 2014; Ma et al.,
2014). However, the exact functional roles of these genetic
variations in the development and progression of schizophrenia
are less understood. Indeed, the functioning of these ncRNAs
in the development of schizophrenia and the correction
of their genetic changes in the genomic DNA, the key
to develop novel therapies for schizophrenia, have been
hampered by insufficient technology to manipulate these
ncRNA genes effectively and a lack of appropriate animal
models. Apparently, understanding these changes in the
genomic DNA, including the coding and non-coding regions in
schizophrenia, in combination with the development of novel
genetic tools, will undoubtedly enable the mutations to be
corrected, which is the key to developing novel therapies for
schizophrenia.
In recent years, with a range of advanced technologies,
including next-generation sequencing, high-resolution
microarrays and genotyping, a great number of miRNAs
and lncRNAs associated with schizophrenia have been identified
and characterized. The understanding of these ncRNAs and
their genetic variations in the development of schizophrenia has
relied on the novel tools of advanced technologies in biology
and beyond. Clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated nuclease 9 (Cas9) is a
recently developed revolutionary gene editing technology that
is able to manipulate effectively the non-coding regions of the
genomic DNA in human cell lines and animal models, to create
or correct the mutations more easily than ever in living cells and
animals, and therefore to overcome obstacles in schizophrenia
research and therapy (Bhaya et al., 2011; Jinek et al., 2012; Cho
et al., 2013; Cong et al., 2013; Jiang et al., 2013; Mali et al., 2013;
Doudna and Charpentier, 2014).
In this review article, we bring together schizophrenia-
associated regulatory ncRNAs, mainly miRNAs and lncRNAs,
summarize CRISPR/Cas9-mediated editing on the non-coding
regions of genomic DNA in human cell lines and animal
models, and propose applications of the revolutionary gene
editing CRISPR/Cas9 tool in schizophrenia research, especially
on the functional study of ncRNAs genes and on the
development of animal models to accelerate schizophrenia
research, thus proving the causal relationship between genetic
defects and the pathophysiology of schizophrenia, and eventually
translating the scientific findings into a clinical cure for
schizophrenia. The information described in the present review
may help researchers to tackle this complex health problem
and perhaps other genetically related mental disorders due to
the overlapping genetic alterations of schizophrenia with other
mental illnesses.
METHODS
A systematic search and review of the recent literature
was performed using the main databases, including PubMed,
Google Scholar and Wanfang Med Online, by using the
following keywords: schizophrenia, mental disorder, gene
editing, CRISPR/Cas9, ncRNAs, miRNAs and lncRNAs.
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ncRNAs INCLUDING miRNAs AND
lncRNAs THAT ARE ASSOCIATED WITH
SCHIZOPHRENIA
The involvement of complex genetic components in the etiology
of schizophrenia has been well established by a wealth of
scientific evidence. Indeed, the heritability of schizophrenia
is approximately 80% (Cardno et al., 1999); therefore, novel
genomic tools offer hope for insight into the profound etiology of
this complicated, genetically relatedmental illness. Genome-wide
association studies have revealed a great number of strong
susceptibility loci for schizophrenia, most of which are located
in the non-coding regions of the genome, including genetic
fragments for the transcription of miRNAs and lncRNAs.
In fact, numerous studies have found that the majority of
miRNAs and lncRNAs are highly expressed in the brain,
where their genetic mutations, abnormal expression and impact
on target gene levels may lead to defective development,
suppression of synaptic efficacy, and mGluR-dependent synaptic
plasticity in the hippocampus (Olde Loohuis et al., 2015; Siegert
et al., 2015) as well as other neurological impairment that
is largely correlated with schizophrenia and may contribute
to its pathogenesis and progression (Krichevsky et al., 2003;
Sempere et al., 2004; Giraldez et al., 2005; Vo et al., 2005;
Schratt et al., 2006). In the past decade or two, with the
help of high-throughput microarray techniques, comparison
of differential expression of miRNAs in schizophrenia vs.
controls has identified numerous miRNAs that are dysregulated
in schizophrenia, which have been summarized previously
(Beveridge and Cairns, 2012; Wang J. et al., 2014). In contrast
to the above studies with microarray analysis, a genome-wide
association study performed in a large-scale population revealed
schizophrenia-associated non-coding genes, including miRNA
genes, among which miRNA137 stands out (International
Schizophrenia Consortium et al., 2009; Schizophrenia Psychiatric
Genome-Wide Association Study (GWAS) Consortium, 2011).
International Schizophrenia Consortium et al. (2009) reported
that the genetic elements for a small ncRNA, the microRNA137
(MIR137) gene with chromosomal location 1p21.3, have been
the schizophrenia-associated loci, conferring susceptibility to
schizophrenia and the discovery has received great attention
within the field. In the following large-scale genome-wide
association study conducted by Franke et al. (2016) using more
than 40,000 recruited participants, the rs1625579 polymorphism
in the miRNA137 gene was identified to be strongly linked
to schizophrenia (Schizophrenia Psychiatric Genome-Wide
Association Study (GWAS) Consortium, 2011; Ma et al.,
2014). To date, many further investigations have supported
the association between miR137 and schizophrenia as well
as the miR-137 variant rs1625579 as a predictor of an
earlier age-at-onset of psychosis in schizophrenia (Lett et al.,
2013). In a Han Chinese population, analysis of the single
nucleotide polymorphism rs1625579 of the miRNA137 gene
in a cohort of 1430 individuals with schizophrenia compared
with 1570 healthy individuals was performed; rs1625579 showed
significant differences in the allele frequencies between those
who suffered from schizophrenia and healthy control subjects
(Guan et al., 2014), while the single nucleotide polymorphism
rs66642155 allelic variant was likely to have an impact on the
age-at-onset and the degree of positive symptoms (Wang S.
et al., 2014). The molecular mechanism whereby the genetic
variants of miR-137 confer a high risk of schizophrenia also
has been shown to be related to a declined fronto-striatal
brain white and gray matter structure but without changes
in the volume of the local brain (Rose et al., 2014; Wright
et al., 2016), which may cause symptoms such as poor
concentration, low processing speed, cognitive impairment,
etc. (Kuswanto et al., 2015); the impact of miR137 genetic
alterations on the expression of a set of target neuronal
transmission genes and synaptogenesis (Kos et al., 2015;
Strazisar et al., 2015; Wright et al., 2015); and involvement
of miR137 on a glucocorticoid receptor-dependent signaling
pathway (Vallès et al., 2014). A very recent in-depth study
in a zebrafish model system by Giacomotto et al. (2016) has
reported that a slight change in synaptic function or a defect
in the axonal network mediated by schizophrenia-associated
suppression of miR-137 is likely responsible for the behavioral
phenotype.
Apart from miRNAs, lnRNAs have emerged as one of
most important classes of ncRNAs in the regulation of gene
expression, and their genetic alterations and dysregulation play
an important role in the pathogenesis of various diseases. In
contrast to a larger number of schizophrenia-associated miRNAs
being studied, only several lncRNAs have been identified
to be correlated with this disease, among which myocardial
infraction-associated transcript (MIAT), also known as retinal
ncRNAs 2, was most recently found to be strongly correlated
with schizophrenia. MIAT was originally identified as a new
member of the lncRNA family in Blackshaw et al. (2004),
and it was initially found to play a role in regulating retinal
cell fate differentiation and to be associated with myocardial
infraction (Ishii et al., 2006; Rapicavoli et al., 2010; Liao et al.,
2016). It is also abundantly expressed in the nucleus of neurons
during development through adulthood. In addition, MIAT
is known as lncRNA Gomafu (Sone et al., 2007), a Japanese
word reflecting its speckled distribution in the nucleoplasm.
Despite its chromosomal location of 22q12.1, which has been
documented to be associated with schizophrenia, and its
expression in the nervous system, the link between this lncRNA
and schizophrenia was unveiled in 2014. The Australian research
team of Barry et al. (2014) has demonstrated for the first time
the strong association of MIAT with schizophrenia, including
downregulation of Gomafu in schizophrenic patients, and has
provided insight into the mechanisms: acutely declined levels
of Gomafu in response to neuronal activation and Gomafu-
mediated impaired alternative splicing through its binding
directly to the two splicing factors QK1 and serine/arginine-
rich splicing factor 1, which ultimately leads to the abnormal
regulation of the two schizophrenia genes DISC-1 and ErbB4
(Barry et al., 2014; Liao et al., 2016), causing a decrease
in the activity of parvalbumin interneurons (Chung et al.,
2016). Soon after the identification of the association between
lncRNA Gomafu and schizophrenia, the link of its genetic
alterations with schizophrenia in different populations has
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been subsequently reported. Rao et al. (2015) have conducted
an analysis on the genetic variants of lncRNA Gomafu in
1255 patients diagnosed with paranoid schizophrenia, compared
to 1209 healthy individuals in a Chinese Han population, and
found that the rs1894720 locus was significantly associated with
paranoid schizophrenia (Rao et al., 2015). Aside from lncRNA
Gomafu, there are other mental disease-related lncRNAs such
as Evf2, BDNF-AS and DISC-2 that have been found to be
associated with schizophrenia and have been reviewed previously
(Merelo et al., 2015).
As the number of new schizophrenia-associated ncRNAs
continues to grow and the variants within the ncRNA genes
may directly correlate with schizophrenia, there is an urgent
need for novel genetic tools that can be used to understand
the functional role of these ncRNAs in schizophrenia and to
correct the mutations as a novel approach for schizophrenia
research and treatment. CRISPR/Cas9 is such a revolutionary
technology that can be applied to work especially for
this purpose.
CRISPR/Cas9 FOR EDITING GENOMIC
ELEMENTS TARGETING NON-CODING
RNAs
The CRISPR/Cas9 system, originally well-documented as an
adaptive immune defense mechanism in bacteria, is an emerging
revolutionary yet feasible technique for precise genome editing
of various organisms, including plants, animals, and even
humans, so that specific changes in the genomic DNA stretches
can be easily and precisely made (Bhaya et al., 2011; Jinek
et al., 2012; Cho et al., 2013; Cong et al., 2013; Jiang et al.,
2013; Mali et al., 2013; Doudna and Charpentier, 2014). The
CRISPR/Cas9 system generally consists of two components:
the Cas9 protein and the guide RNA (gRNA). Being guided
by the gRNA, the Cas9 protein is recruited to the target
site and is able to cut the genomic DNA at a specific site.
The past years have witnessed the emergence of this innovative
technology as well as dramatic progress in genomic DNA
editing with the CRISPR/Cas9 system (Doudna and Charpentier,
2014). The technology has been applied to manipulate the
genomic DNA elements targeting not only the coding regions
but also the non-coding ones, from which small and long
coding ncRNAs such as miRNAs and lncRNAs are encoded.
It is particularly important to edit the genomic DNA elements
targeting non-coding regions, since silencing these ncRNA
genes with the current, conventional RNA interference (RNAi)
technology has turned out to be challenging due to their
resistance to the RNAi techniques (Zamore et al., 2000; Gilbert
et al., 2013; Fatica and Bozzoni, 2014; Hilton et al., 2015).
Recently, the obstacles have been overcome by the application
of a modified CRISPR/Cas9 system, in which a lentiviral
vector expressing two gRNAs are used simultaneously, with
which the genomic DNA fragments ranging from 100 to
3000 bp in length have been manipulated and edited (Han
et al., 2014; Aparicio-Prat et al., 2015). To date, a number
of ncRNA genes in the genomic DNA have been successfully
silenced, including miRNAs (miR21, miR29a) and lncRNAs
(UCA1, MALAT1), with MALAT1 reduced by up to 98%
inside human HCT116, Hela, and HEK293T cell lines after
the promoter region of the MALAT1 gene was edited by
the Double Excision CRISPR Knockout method (Aparicio-
Prat et al., 2015; Ho et al., 2015; Chang et al., 2016). More
detailed information about the miRNA and lncRNA genes
successfully edited by the CRIPSR/Cas9 system in cell lines
and entire animals were summarized in Tables 1, 2. This
powerful genome-editing tool has brought a wealth of innovative
applications and perspectives for both biological research and
the treatment of diseases, including the complicated disease
of schizophrenia. In the following sections, we offer a review
of a number of successful examples of CRISPR/Cas9-mediated
editing on the non-coding regions of genomic DNA in human
TABLE 1 | Summary of the miRNA genes successfully edited by the CRISPR/Cas9 system.
miRNA Chromosomal
location
Cells/Animals
tested
Results Reference
miR-21 Chr17 Human HEK293,
LNCaP, MCF-7
and HCT-116 cells
The miR-21 gene was knocked out with over 90%
reduction of the miR-21 levels
Ho et al. (2015)
miR-29a Chr7 Human HEK293 cells Complete knock-out of the miR-29a gene Ho et al. (2015)
miRNA cluster
(miR-17a-1,
miR-92a-1)
Chr1 Zebrafish The deletion of this miRNA cluster gene from dre-miR-
17a-1 to dre-miR-92a-2 was obtained in the zebrafish
embryos injected with the CRISPR/Cas9 in combination
with the gRNAs
Xiao et al. (2013)
miR-17 Chr13 Human HCT-116
and HT-29 cells
The miR-17 expression was decreased by up to 96%
and the knock-down phenotype was stable in the human
cells and mice
Chang et al. (2016)
Mice
miR-141 Chr12 Human HCT-116
and HT-29 cells
Nearly 96% reduction in the miR-141 levels was
achieved with long-term stability of the knock-down
phenotype and in control of crossing off-target effect on
other members in the same family
Chang et al. (2016)
Mice
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TABLE 2 | Summary of the lncRNA genes successfully edited by the CRISPR/Cas9 system.
miRNA Chromosomal
location
Cells/Animals
tested
Results Reference
UCA1 Chr19 Human HCT-116 cells After >5.6 kb in length for the UCA1 gene was edited,
UCA1 RNA levels were reduced by about 90%
Ho et al. (2015)
MALAT1 or
NEAT1
Chr11 Human cell lines: HEK293T,
HCT-116, Hela and IMR90
Up to 98%reduction in MALAT1 RNA expression was
achieved after the upstream and major promoters in the
MALAT1 gene were deleted
Aparicio-Prat et al. (2015)
LncRNA-21A Chr8 Human HCT-116 cells 475 bp for the lncRNA-21 A gene was targeted,
wild-type lncRNA-21A was completely lost
Ho et al. (2015)
AK023948 Chr8 Human MCF-7 cells The AK023948 gene was knocked out Ho et al. (2015)
LncRNA Rian Chr12 Mice 23 kb fragment in the lncRNA Rian gene was deleted,
and a Rian knock-out mouse model with heritability of
this large fragment deletion was established
Han et al. (2014)
Abbreviations: UCA1, urothelial cancer associated 1; MALAT1, metastasis associated lung adenocarcinoma transcript 1; NEAT2, noncoding nuclear-enriched abundant
transcript 2.
cell lines and animal models as well as comment on the
perspectives for both schizophrenia research and an eventual
cure for schizophrenia. We also discuss the challenges of
translating this advanced technology into a clinical therapy for
schizophrenia and suggest strategies for removing the obstacles
to accelerate the pace along the path from the bench to the
bedside.
PERSPECTIVE OF EDITING ncRNA GENES
WITH CRISPR/Cas9 FOR SCHIZOPHRENIA
RESEARCH
The application of the novel CRISPR/Cas9 technology in
schizophrenia-associated ncRNAs will usher in a new perspective
for schizophrenia research to advance our understanding about
the biological function for ncRNAs and to facilitate creating
animal models with specific mutations or with the original
form restored. Silencing or enhancing gene expression to lose
or gain function has been well accepted in the study of a
gene of interest. RNAi with specific small-interfering RNAs
(siRNAs) is a commonly used approach to silence a desired
gene encoded by the coding regions of genomic DNA, which
usually occurs in the cytoplasm (Zamore et al., 2000). However,
siRNAs designed to target ncRNA genes, including lncRNAs
and miRNA genes, have been found to be inefficient mainly
because many lncRNAs are located in the nucleus (Fatica
and Bozzoni, 2014). In fact, it has been difficult to achieve
successful knockdown of a desired lncRNA gene. Recently,
scientists from independent research groups have applied a
modified CRISPR/Cas9 system to target the ncRNA genes
in the nucleus that has resulted in robust knockdown of
a number of ncRNAs, including miRNAs in the zebrafish
genome (Xiao et al., 2013), miRNAs in human cell lines,
lncRNAs in a mouse model (Han et al., 2014) and lncRNAs
in human cell lines (Ho et al., 2015), allowing the study of
the biological roles of schizophrenia-associated ncRNAs in the
pathogenesis of schizophrenia. The key feature of the modified
CRISPR/Cas9 system is the use of dual gRNAs, which produce
two cuts in specific sites and allow deletion of a larger fragment
(Ho et al., 2015). With the modified CRISPR/Cas9 system,
there is the possibility to manipulate any exon fragment
of the ncRNAs and to explore the biological function of
these ncRNA genes in schizophrenia. Since schizophrenia is
a complex disorder that involves multiple genetic alterations
of ncRNAs, the modified CRISPR/Cas9 approach will enable
the disruption of these ncRNAs and will test if disruption
of these ncRNA genes can cause schizophrenia. Apart from
the silencing of ncRNA genes, the CRISPR/Cas9 system can
also deliver regulatory components to the target genes and
activate or upregulate target gene expression. Together with
its silencing of the ncRNA gene, activation of the gene at the
transcriptional level also empowers researchers to understand the
biological role for a gene in the development and progression
of schizophrenia. Apparent knockdown or activation of an
ncRNA gene using the modified CRISPR/Cas9 system has
couple of advantages: it is more effective than RNAi, and
it is able to target multiple genes simultaneously. When it
comes to the schizophrenia-associated ncRNAs miR137 and
Gomafu, it is possible to target these two ncRNAs simultaneously
and investigate if miRNA137 and Gomafu each alone or
in combination affect the development and progression of
schizophrenia.
The main bottleneck of schizophrenia research has been
lack of translatable animal model system to prove causal
relationship between genetic defects and pathophysiology of
schizophrenia owing to not only difficulties in reproducing its
prominent symptoms but also the tedious work required for
creating animal models with specific genomic mutations. The
CRISPR/Cas9 system brings a novel perspective for developing
animal models for schizophrenia research due to a number of
advantages. With the help of the CRISPR/Cas9 system, specific
mutations of the target ncRNA gene can be introduced into
the embryo and the normal form of the ncRNA gene can
be restored in a rat or mouse embryo. The rat or mouse as
well as its offspring will contain the mutation or restoration
of the original form, which allows researchers to compare the
symptoms directly, to determine how disruption of these genes
affects the development and progression of schizophrenia, and
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to pinpoint the underlying molecular pathway in those animal
models. The generated animal models can also be used to test the
efficacy of medications or other potential therapeutic approaches
in the treatment of schizophrenia. In fact, the animal model
generated by traditional procedures usually takes up to 2 years
to get the specific mutations in the offspring because multiple
breeding steps are needed, while creating the animal model using
the CRISPR/Cas9 approach only requires about 2 months and
costs less. Furthermore, in combination with template DNAs
and using multiple gRNAs, the CRISPR/Cas9 system is able to
introduce a number of desired mutations into the embryo of an
animal or their offspring, which is not likely to work out with
other previous approaches.
PERSPECTIVE OF EDITING ncRNA GENES
WITH CRISPR/Cas9 FOR THE TREATMENT
OF SCHIZOPHRENIA
Medications have been the cornerstone therapy for
schizophrenia, and medications in combination with
psychosocial interventions are widely used to manage
schizophrenia. However, medications for schizophrenia usually
cause serious adverse side effects; therefore, a large portion of
patients with schizophrenia fail to take medications, leading
to this devastating mental disease being uncontrolled. As a
strong genetic component is involved in the pathogenesis
of schizophrenia, multiple alterations in the genomic DNA
of neurons have been implicated as causative factors, and
fortunately great progress has been recently made in both
identifying critical genomic regions and developing advanced
genetic technologies, multiple alterations may be manipulated
in the genomic DNA of neurons. As we discussed earlier, the
genetic mutations in both miRNA and lncRNA genes have
been directly linked to schizophrenia. The CRISPR/Cas9 system
has provided a valuable tool to correct mutations not only in
inheritable genetic diseases but also gene mutations in DNA
genomes related to diseases, including ncRNAs genes. The
CRISPR/Cas9 system, together with a donor DNA template, is
required and delivered together with the CRISPR/Cas9 system
into the recipients, and it has been successfully used to replace the
mutations with substitutions in cells, plants, and entire animals
to correct certain genomic DNA mutations. For example, a
research group from Duke University has recently explored
the application of the CRISPR/Cas9 system to treat Duchenne
muscular dystrophy (DMD), a genetic disease with a debilitating
mutation within one of the exons of the dystrophin gene
(Nelson C. E. et al., 2016). For the first time, researchers have
successfully treated a human disease in a living mouse model
(Nelson C. E. et al., 2016) with the CRISPR/Cas9 gene editing
technology. Meanwhile, similar results from two other research
groups from Harvard University and the University of Texas
are exciting as well (Long et al., 2016; Tabebordbar et al., 2016).
These three independent research groups have demonstrated that
correction of the dystropin gene, the consequential restoration of
functional dystrophin, and the enhancement of muscle strength
can be achieved after one of the exons in the dystrophin gene
was reverted with the CRISPR/Cas9 technique by using different
methods to deliver the CRISPR/Cas9 components (Long et al.,
2016; Nelson C. E. et al., 2016; Tabebordbar et al., 2016).
In addition to DMD, a variety of other genetic diseases such
as sickle-cell anemia and Alzheimer’s disease have been treated
with the CRISPR/Cas9 technique by correcting the causative
mutations and reverting the defect to the original form in
the genomic DNA, and functional restoration has been gained
(Huang et al., 2015; Sankaran and Weiss, 2015; Paquet et al.,
2016). Recently, a research team from Sun-Yatsen University in
Guangzhou, China, has explored, for the first time, the utilization
of this novel CRISPR/Cas9 system to edit the thalassemia-causing
gene in human embryos (Liang et al., 2015; Callaway, 2016).
As a result, a number of human embryos have successfully
gained the corrected form of the target gene. More recently,
the successful application of the CRISPR/Cas9 gene editing
technique to human induced pluripotent stem cells (IPSCs) have
been reported to generate disease model (Horii et al., 2013) and
to treat effectively a number of diseases, including epi-dermolysis
bullosa (Osborn et al., 2013), b-thalassemia (Ma et al., 2013),
a1-antitrypsin deficiency (Choi et al., 2013), AIDS (Ye et al.,
2014), and Niemann-Pick Type C (Maetzel et al., 2014), DMD
(Li et al., 2014). Therefore, this novel approach has provided
enormous promise for gene therapy of many other forms of
diseases including schizophrenia.
Despite the use of genome editing technologies including
zinc finger nucleases, TALENS, and CRISPR/Cas9 has opened
up the possibility of in vivo genome editing therapy. Unlike
peripheral nerve disorder such as DMD, brain and mental
disorders (i.e., Parkinson’s disease and schizophrenia) have a
unique challenge in clinical settings. AAVs vectors, which have
been recently approved by FDA for a clinical use, have effectively
delivered the nucleases and other components to a variety of
tissues including brain. Compared to the other genome editing
approaches, the gRNA sequence used in the CRISPR/Cas9 system
is more easily to be altered than for TALEs, and a much shorter
gRNA and multiple gRNAs can be used to result in multiple
DNA cuts (Hsu et al., 2014; Cox et al., 2015) suggesting more
promising for the use of CRISPR/Cas9 as a potential therapeutic
intent. Most recently, Deverman et al. (2016) reported that they
developed a harmless virus, namely AAV-PHP.B, to across the
blood brain barrier to successfully deliver treatment to the brain.
These exciting results in living mammals and human cells
show great potential for treating human diseases by translating
this CRISPR/Cas9 system to a novel therapeutic approach to treat
genetically related diseases in humans, including schizophrenia
and perhaps other genetically related mental disorders due to
the overlapping genetic alterations of schizophrenia with other
mental illnesses.
CHALLENGES AND FUTURE DIRECTIONS
Despite the remarkable progress, the CRISPR/Cas9 system is still
immature and has some limitations and challenges to overcome.
Technical improvement is needed, while ethical issues require
resolution as well. There are a couple of technical challenges,
including specificity, efficiency of the system and penetration of
the blood-brain barrier for delivery of the components in the
Frontiers in Molecular Neuroscience | www.frontiersin.org 6 February 2017 | Volume 10 | Article 28
Zhou et al. CRISPR/Cas9 Editing ncRNA Genes for Schizophrenia
CRISPR/Cas9 system. When a potential therapeutic approach to
treat brain and mental disorders is discovered, the blood-brain
barrier always poses an obstacle for the drugs to reach the brain
cells. The components themselves in the CRISPR/Cas9 system
cannot pass through the blood-brain barrier. In an effort to
deliver the CRISPR/Cas9 components, a few inactive genetically
engineered viruses have been successfully used as a carrier
that can be packed with the CRISPR/Cas9 components, cross
the blood-brain barrier, and finally unload those molecules
in the brain cells. In spite of having no capacity to cause
disease, further improvement of the efficiency and the evaluation
of long-term safety are needed. In addition to the above-
mentioned technical concerns, there are ethical issues as well
for manipulating genomic DNA in human sperm, eggs and
embryos, mainly because of limited knowledge regarding the
CRISPR/Cas9 system and the long-term impact of genetic
disruption and off-targeting on future generations (Krishan et al.,
2016). To date, ncRNAs have not been reported to express
proteins; Nelson B. R. et al. (2016) have recently reported that
a lnRNA encodes a peptide with the ability to enhance SERCA
activity in muscle. With the possibility of unidentified proteins
being translated by ncRNAs, it is uncertain whether the proteins
may exert any unfavorable, even disease-related activity. All of
these new questions require answers; therefore, along with other
issues, there is still a long way to go before this revolutionary
technology is translated into a clinical cure for schizophrenia
and possibly other mental diseases as well due to significant
overlaps of the risk genes shared by different forms of psychiatric
disorders.
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